Metered-dose and safety and compliance packaging for systemic anticancer therapy
A therapeutic agent and compliance technology, applied in the direction of anti-tumor drugs, organic active ingredients, and oral feeding equipment, etc., can solve the problems of complex compliance, toxicity and death of anti-tumor chemical agents, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0191] Theoretical systemic exposure to uracil resulting from topical application of 1% (w / w) uracil ointment to hands and feet can be roughly estimated as follows.
[0192] Application of 0.1 g of 1% (w / w) uracil ointment 4 times daily to hands and feet represents a daily exposure of 4-8 mg uracil. Topical absorption of the agent through intact skin can be on the order of 1%, which results in systemic absorption of 40-8 g / day. This is in contrast to the daily exposure of uracil in UFT of approximately 1200 mg. Thus, mean systemic uracil exposure with uracil ointment averaged about 0.00005 times (0.005%) that of UFT.
[0193] However, on the surface of the skin, and just below the skin, the concentration of uracil should be about 10 mg / ml. A useful estimate of mean plasma 5-FU concentration is 0.5 pg / ml. Thus, topical administration of uracil ointment theoretically establishes a local concentration of uracil approximately 2000 times that of 5-FU at the skin, with a systemic...
Embodiment 2
[0195] A 48-year-old female patient presented with metastatic breast cancer. She has declined mastectomy and has previously failed on the following drugs: doxorubicin and cyclophosphamide, one week of paclitaxel, and one week of norvinblastine. Then Xeloda She was treated with 1% uracil ointment applied to the hands and feet. Using Xeloda The fifth cycle of treatment started with 1% uracil ointment.
[0196] Table 1 below summarizes the results in this patient.
[0197]
[0198] *ND: not described
[0199] The 1% uracil ointment makes Xeloda The dose can be escalated again, the Xeloda Anticancer activity at high doses. The 1% uracil ointment allows administration of high doses of It has improved anticancer efficacy (compare columns 5 and 6). The 1% uracil ointment did not have any visible toxicity.
Embodiment 3
[0201] Another patient, a 68-year-old Caucasian male diagnosed with metastatic colon cancer, was treated with and thalidomide for treatment. Hand-foot syndrome develops. Complete reversal of the symptoms occurred after treatment with topical 1% uracil ointment. The effect of treatment with thalidomide was not affected by the simultaneous use of 0.1 g 1% uracil ointment 4 times a day. There was no dose reduction or treatment delay of chemotherapy.
PUM
| Property | Measurement | Unit |
|---|---|---|
| thickness | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More